ATE384523T1 - Abbaufragmente des bilirubins oder des biliverdins - Google Patents
Abbaufragmente des bilirubins oder des biliverdinsInfo
- Publication number
- ATE384523T1 ATE384523T1 AT01907912T AT01907912T ATE384523T1 AT E384523 T1 ATE384523 T1 AT E384523T1 AT 01907912 T AT01907912 T AT 01907912T AT 01907912 T AT01907912 T AT 01907912T AT E384523 T1 ATE384523 T1 AT E384523T1
- Authority
- AT
- Austria
- Prior art keywords
- heterocyclyl
- alkynyl
- alkenyl
- aryl
- alkyl
- Prior art date
Links
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 title abstract 6
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 title abstract 3
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000000304 alkynyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 abstract 2
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 abstract 2
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000006575 electron-withdrawing group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/728—Bilirubin; including biliverdin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/822—Identified hapten
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0004549.2A GB0004549D0 (en) | 2000-02-25 | 2000-02-25 | Degradation fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE384523T1 true ATE384523T1 (de) | 2008-02-15 |
Family
ID=9886450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01907912T ATE384523T1 (de) | 2000-02-25 | 2001-02-26 | Abbaufragmente des bilirubins oder des biliverdins |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7098238B2 (de) |
| EP (1) | EP1272178B1 (de) |
| JP (1) | JP2003525881A (de) |
| AT (1) | ATE384523T1 (de) |
| AU (1) | AU2001235779A1 (de) |
| DE (1) | DE60132570T2 (de) |
| ES (1) | ES2300317T3 (de) |
| GB (1) | GB0004549D0 (de) |
| WO (1) | WO2001062245A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504243B2 (en) * | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
| DK3088353T3 (da) | 2013-12-27 | 2020-02-24 | Bilix Co Ltd | Bilirubinpartikler og deres fremstilling til anvendelse i terapi |
| CN111544588B (zh) * | 2020-05-12 | 2021-09-28 | 中国科学院过程工程研究所 | 一类免疫活性肽-胆绿素的缀合物、其制备方法及应用 |
| WO2024010353A1 (ko) * | 2022-07-05 | 2024-01-11 | 주식회사 빌릭스 | 페길화된 빌리루빈을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989625A (en) * | 1975-02-25 | 1976-11-02 | Ma-De Inc. | Detector for air in blood dialysis systems |
| CH635828A5 (de) * | 1978-08-30 | 1983-04-29 | Ciba Geigy Ag | N-substituierte imide und bisimide. |
| CA2134077C (en) | 1992-04-23 | 2002-05-21 | Thaddeus R. Nieduzak | 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy |
| JP3230062B2 (ja) | 1992-10-10 | 2001-11-19 | 株式会社バイオシステム | 新規なトリピロール誘導体 |
| US5380667A (en) * | 1992-10-30 | 1995-01-10 | The United States Of America As Represented By The Secretary Of The Air Force | Serum bilirubin and liver function tests as risk predictors for coronary artery disease |
| US5840701A (en) | 1993-08-16 | 1998-11-24 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| JPH08151365A (ja) | 1994-11-25 | 1996-06-11 | Hiromu Nakajima | ビリルビン酸化生成物、および病態の診断方法 |
| CA2175178A1 (en) | 1995-06-06 | 1996-12-07 | Anthony D. Buttitta | Non-invasive bilirubin monitor |
| JP3747511B2 (ja) | 1996-04-03 | 2006-02-22 | 東ソー株式会社 | マレイミド類の製造方法 |
| ATE344454T1 (de) | 1996-04-18 | 2006-11-15 | Medical Res Council | Oxydativer stoffwechsel in glatten muskelzellen: verfahren in beziehung dazu |
| US6093709A (en) | 1996-08-22 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for sexual dysfunctions |
-
2000
- 2000-02-25 GB GBGB0004549.2A patent/GB0004549D0/en not_active Ceased
-
2001
- 2001-02-26 EP EP01907912A patent/EP1272178B1/de not_active Expired - Lifetime
- 2001-02-26 DE DE60132570T patent/DE60132570T2/de not_active Expired - Lifetime
- 2001-02-26 US US10/204,950 patent/US7098238B2/en not_active Expired - Fee Related
- 2001-02-26 AU AU2001235779A patent/AU2001235779A1/en not_active Abandoned
- 2001-02-26 ES ES01907912T patent/ES2300317T3/es not_active Expired - Lifetime
- 2001-02-26 AT AT01907912T patent/ATE384523T1/de not_active IP Right Cessation
- 2001-02-26 WO PCT/GB2001/000830 patent/WO2001062245A2/en not_active Ceased
- 2001-02-26 JP JP2001561311A patent/JP2003525881A/ja active Pending
-
2006
- 2006-06-30 US US11/479,024 patent/US7498421B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB0004549D0 (en) | 2000-04-19 |
| DE60132570D1 (de) | 2008-03-13 |
| AU2001235779A1 (en) | 2001-09-03 |
| WO2001062245A2 (en) | 2001-08-30 |
| EP1272178B1 (de) | 2008-01-23 |
| US20030162826A1 (en) | 2003-08-28 |
| EP1272178A2 (de) | 2003-01-08 |
| ES2300317T3 (es) | 2008-06-16 |
| WO2001062245A3 (en) | 2001-12-20 |
| DE60132570T2 (de) | 2009-01-29 |
| US7098238B2 (en) | 2006-08-29 |
| JP2003525881A (ja) | 2003-09-02 |
| US20070015816A1 (en) | 2007-01-18 |
| US7498421B2 (en) | 2009-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0109011A (pt) | Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica | |
| HUP0203165A2 (hu) | Nitrogént tartalmazó, öttagú heterociklusos vegyületek | |
| EA200300333A1 (ru) | Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7 | |
| ATE272633T1 (de) | Aromatische amiden | |
| MY157884A (en) | Peroxisome proliferator activated receptor alpha agonists | |
| ES2121441T3 (es) | Nuevos derivados de 3,5 -dioxo - (2h,4h) - 1,2,4 - triazina,su preparacion y aplicacion como farmaco | |
| CA2428271A1 (en) | Cyanopyrrolidine derivatives as inhibitors of dpp-iv | |
| TW200505874A (en) | New compounds with therapeutic effect | |
| IL153594A0 (en) | Amino alcohol derivatives and pharmaceutical compositions containing the same | |
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| ES2124545T3 (es) | Azolidindionas como agentes antihiperglucemicos. | |
| ATE374765T1 (de) | Substituierte heterocyclische amide | |
| BR0309447A (pt) | Composto, agente, processos para a preparação dos mesmos, e para o combate do crescimento de plantas indesejadas, e, uso do composto | |
| NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| BG104853A (en) | Thienylazolylalcoxyethanamines, their preparation and their application as medicaments | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| NZ331801A (en) | Therapeutic agent for diabetes | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| ATE450496T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE409180T1 (de) | Synthese von zyklopentadien derivaten | |
| RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
| MY137964A (en) | Benzofuran derivative | |
| ATE384523T1 (de) | Abbaufragmente des bilirubins oder des biliverdins | |
| CA2357038A1 (en) | Medical compositions comprising 1,4-benzothiazepine derivatives for the treatment of atrial fibrillation | |
| WO1998053790A3 (en) | Compounds that inhibit the binding of vascular endothelial growth factor to its receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |